Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 24.25 GBp
Change Today 0.00 / 0.00%
Volume 198.7K
SCLP On Other Exchanges
As of 11:35 AM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

scancell holdings plc (SCLP) Snapshot

24.25 GBp
Previous Close
24.25 GBp
Day High
24.25 GBp
Day Low
24.25 GBp
52 Week High
06/1/15 - 44.75 GBp
52 Week Low
03/31/15 - 22.75 GBp
Market Cap
Average Volume 10 Days
-0.01 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for SCANCELL HOLDINGS PLC (SCLP)

Related News

No related news articles were found.

scancell holdings plc (SCLP) Related Businessweek News

No Related Businessweek News Found

scancell holdings plc (SCLP) Details

Scancell Holdings PLC, a biopharmaceutical company, engages in the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer based on its ImmunoBody and Moditope technology platforms in the United Kingdom. It is involved in the development of SCIB1, a plasmid DNA vaccine, which is in I/II clinical trials for the treatment of stage III/IV melanoma; and SCIB2 to treat cancer antigen NY-ESO-1. The company has collaborations with Cancer Research Technology Limited; Immatics Biotechnologies GmbH; NIH; Ichor Medical Systems; and Merck KGaA. Scancell Holdings PLC was incorporated in 2008 and is based in Nottingham, the United Kingdom.

10 Employees
Last Reported Date: 09/18/15
Founded in 2008

scancell holdings plc (SCLP) Top Compensated Officers

Joint Chief Executive Officer, Chief Scientif...
Total Annual Compensation: 10.0K GBP
Joint Chief Executive Officer and Director
Total Annual Compensation: 10.0K GBP
Development Director and Director
Total Annual Compensation: 100.0K GBP
Compensation as of Fiscal Year 2015.

scancell holdings plc (SCLP) Key Developments

Scancell Holdings plc Announces Audited Consolidated Earnings Results for the Year Ended April 30, 2015

Scancell Holdings PLC announced audited consolidated earnings results for the year ended April 30, 2015. For the year, the company's operating loss was GBP 2,959,995 against GBP 2,497,220 a year ago. The increased loss for the period has been as a result of additional expenditure on the SCIB1 clinical trials and the further development of Moditope. Loss before taxation was GBP 2,828,482 against GBP 2,468,034 a year ago. Loss and total comprehensive income was GBP 2,414,630 or 1.07 pence per basic and diluted share against GBP 2,222,954 or 1.03 pence per basic and diluted share a year ago. Net cash used in operating activities was GBP 2,638,747 against GBP 2,093,367 a year ago. Asset acquisition was GBP 22,930 a year ago.

Scancell and ImmunID Announce Collaboration to Predict SCIB1 Responders Using ImmunTraCkeR

Scancell Holdings plc and ImmunID announce an agreement to collaborate on a research project aimed at predicting which patients will respond best to SCIB1 treatment. The study will use ImmunID's clinical product, ImmunTraCkeR, before and during treatment, to assess the immune-modulatory effect of Scancell's SCIB1 ImmunoBody vaccine in patients with Stage III/IV metastatic melanoma. The ImmunTraCkeR assay will be used to: understand pre-existing immunity of Stage III/IV metastatic melanoma patients; monitor T cell diversity over time in order to assess immune-modulatory effect of the SCIB1 cancer vaccine; make a preliminary assessment of ImmunTraCkeR acting as a predictor of response to SCIB1; and identify any other predictive or prognostic clinical value of T cell diversity. Scancell's first ImmunoBody, SCIB1, is being developed for the treatment of melanoma and is currently being evaluated in a Phase 1/2 clinical trial. The latest data suggests that SCIB1 may have the potential to significantly extend survival times, especially in patients with resected disease.

Scancell Holdings plc Closes Recruitment for SCIB1 Trial

Scancell Holdings plc announced that it has closed patient recruitment for its SCIB1 ImmunoBody Phase 1/2 clinical trial in patients with Stage III/IV melanoma. The Phase 1/2 clinical trial, conducted across five UK centres, is an open label, non-randomised study to determine the safety and tolerability of SCIB1 administered intramuscularly using an electroporation device (TriGrid Delivery System, manufactured by Ichor Medical Systems, USA). Part 1 was a dose-escalation designed trial to determine the dose for Part 2. While the primary objective of the study is to access safety and tolerability, the study is also assessing immune response and anti-tumour activity, and the ability of SCIB1 to delay or prevent disease recurrence in patients with resected disease. In total, 35 patients have now been treated with SCIB1, including ten patients at the higher 8mg dose. Six patients remain on long-term treatment and have received between one and nine additional 4mg or 8mg doses of SCIB1 every three to six months. The last patient in the formal six month study will be dosed in October this year after which the Company will analyse the data and prepare a clinical study report. Patients on long-term continuation treatment will continue to be dosed for up to five years from the start of their treatment regime.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCLP:LN 24.25 GBp 0.00

SCLP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SCLP.
View Industry Companies

Industry Analysis


Industry Average

Valuation SCLP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SCANCELL HOLDINGS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at